CRBN and Miyoshi myopathy: Overall, both iberdomide and mezigdomide offer improved profiles compared to lenalidomide and pomalidomide in terms of cereblon binding, specificity as a single S isomer, targeted protein degradation, tumor anti-proliferation, tumor apoptosis, immune stimulation, and synergistic combinability (Figure 2) [43,50,57,62], with these aspects being suggestive specifically of a unique clinical profile for mezigdomide in MM.